Search Results - "Journal for immunotherapy of cancer"

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death by Galluzzi, Lorenzo, Vitale, Ilio, Warren, Sarah, Adjemian, Sandy, Agostinis, Patrizia, Martinez, Aitziber Buqué, Chan, Timothy A, Coukos, George, Demaria, Sandra, Deutsch, Eric, Draganov, Dobrin, Edelson, Richard L, Formenti, Silvia C, Fucikova, Jitka, Gabriele, Lucia, Gaipl, Udo S, Gameiro, Sofia R, Garg, Abhishek D, Golden, Encouse, Han, Jian, Harrington, Kevin J, Hemminki, Akseli, Hodge, James W, Hossain, Dewan Md Sakib, Illidge, Tim, Karin, Michael, Kaufman, Howard L, Kepp, Oliver, Kroemer, Guido, Lasarte, Juan Jose, Loi, Sherene, Lotze, Michael T, Manic, Gwenola, Merghoub, Taha, Melcher, Alan A, Mossman, Karen L, Prosper, Felipe, Rekdal, Øystein, Rescigno, Maria, Riganti, Chiara, Sistigu, Antonella, Smyth, Mark J, Spisek, Radek, Stagg, John, Strauss, Bryan E, Tang, Daolin, Tatsuno, Kazuki, van Gool, Stefaan W, Vandenabeele, Peter, Yamazaki, Takahiro, Zamarin, Dmitriy, Zitvogel, Laurence, Cesano, Alessandra, Marincola, Francesco M

“…Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display…”
Get full text

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors by Das, Satya, Johnson, Douglas B.

“…Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with many advanced malignancies, only 15–60% of patients…”
Get full text

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events by Brahmer, Julie R, Abu-Sbeih, Hamzah, Ascierto, Paolo Antonio, Brufsky, Jill, Cappelli, Laura C, Cortazar, Frank B, Gerber, David E, Hamad, Lamya, Hansen, Eric, Johnson, Douglas B, Lacouture, Mario E, Masters, Gregory A, Naidoo, Jarushka, Nanni, Michele, Perales, Miguel-Angel, Puzanov, Igor, Santomasso, Bianca D, Shanbhag, Satish P, Sharma, Rajeev, Skondra, Dimitra, Sosman, Jeffrey A, Turner, Michelle, Ernstoff, Marc S

“…Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes…”
Get full text

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors by Davis, Andrew A., Patel, Vaibhav G.

“…The development of immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor types. Despite encouraging and…”
Get full text

TIGIT in cancer immunotherapy by Chauvin, Joe-Marc, Zarour, Hassane M

“…Tumors evade immune-mediated recognition through multiple mechanisms of immune escape. On chronic tumor antigen exposure, T cells become…”
Get full text

Cytokine release syndrome by Shimabukuro-Vornhagen, Alexander, Gödel, Philipp, Subklewe, Marion, Stemmler, Hans Joachim, Schlößer, Hans Anton, Schlaak, Max, Kochanek, Matthias, Böll, Boris, von Bergwelt-Baildon, Michael S

“…During the last decade the field of cancer immunotherapy has witnessed impressive progress. Highly effective immunotherapies such as immune checkpoint…”
Get full text

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group by Puzanov, I, Diab, A, Abdallah, K, Bingham, 3rd, C O, Brogdon, C, Dadu, R, Hamad, L, Kim, S, Lacouture, M E, LeBoeuf, N R, Lenihan, D, Onofrei, C, Shannon, V, Sharma, R, Silk, A W, Skondra, D, Suarez-Almazor, M E, Wang, Y, Wiley, K, Kaufman, H L, Ernstoff, M S

“…Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents…”
Get full text

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations by Gong, Jun, Chehrazi-Raffle, Alexander, Reddi, Srikanth, Salgia, Ravi

“…Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) blockade as a potential form of…”
Get full text

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) by Cohen, Ezra E W, Bell, R Bryan, Bifulco, Carlo B, Burtness, Barbara, Gillison, Maura L, Harrington, Kevin J, Le, Quynh-Thu, Lee, Nancy Y, Leidner, Rom, Lewis, Rebecca L, Licitra, Lisa, Mehanna, Hisham, Mell, Loren K, Raben, Adam, Sikora, Andrew G, Uppaluri, Ravindra, Whitworth, Fernanda, Zandberg, Dan P, Ferris, Robert L

“…Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000…”
Get full text

Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future by Alzeibak, Razan, Mishchenko, Tatiana A., Shilyagina, Natalia Y., Balalaeva, Irina V., Vedunova, Maria V., Krysko, Dmitri V.

“…The past decade has witnessed major breakthroughs in cancer immunotherapy. This development has been largely motivated by cancer cell evasion of immunological…”
Get full text

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project by Merino, Diana M, McShane, Lisa M, Fabrizio, David, Funari, Vincent, Chen, Shu-Jen, White, James R, Wenz, Paul, Baden, Jonathan, Barrett, J Carl, Chaudhary, Ruchi, Chen, Li, Chen, Wangjuh (Sting), Cheng, Jen-Hao, Cyanam, Dinesh, Dickey, Jennifer S, Gupta, Vikas, Hellmann, Matthew, Helman, Elena, Li, Yali, Maas, Joerg, Papin, Arnaud, Patidar, Rajesh, Quinn, Katie J, Rizvi, Naiyer, Tae, Hongseok, Ward, Christine, Xie, Mingchao, Zehir, Ahmet, Zhao, Chen, Dietel, Manfred, Stenzinger, Albrecht, Stewart, Mark, Allen, Jeff

“…BackgroundTumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive…”
Get full text

LAG-3: from molecular functions to clinical applications by Maruhashi, Takumi, Sugiura, Daisuke, Okazaki, Il-Mi, Okazaki, Taku

“…To prevent the destruction of tissues owing to excessive and/or inappropriate immune responses, immune cells are under strict check by various regulatory…”
Get full text

Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity by Efimova, Iuliia, Catanzaro, Elena, Van der Meeren, Louis, Turubanova, Victoria D, Hammad, Hamida, Mishchenko, Tatiana A, Vedunova, Maria V, Fimognari, Carmela, Bachert, Claus, Coppieters, Frauke, Lefever, Steve, Skirtach, Andre G, Krysko, Olga, Krysko, Dmitri V

“…BackgroundImmunotherapy represents the future of clinical cancer treatment. The type of cancer cell death determines the antitumor immune response and thereby…”
Get full text

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma by Zheng, Yi, Wang, Tingting, Tu, Xiaoxuan, Huang, Yun, Zhang, Hangyu, Tan, Di, Jiang, Weiqin, Cai, Shunfeng, Zhao, Peng, Song, Ruixue, Li, Peilu, Qin, Nan, Fang, Weijia

“…Checkpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC)…”
Get full text

Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy by Cannarile, Michael A, Weisser, Martin, Jacob, Wolfgang, Jegg, Anna-Maria, Ries, Carola H, Rüttinger, Dominik

“…The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells…”
Get full text

Mechanisms regulating PD-L1 expression on tumor and immune cells by Chen, Shuming, Crabill, George A., Pritchard, Theresa S., McMiller, Tracee L., Wei, Ping, Pardoll, Drew M., Pan, Fan, Topalian, Suzanne L.

“…BackgroundThe PD-1/PD-L1 checkpoint is a central mediator of immunosuppression in the tumor immune microenvironment (TME) and is primarily associated with…”
Get full text

Tim-3 finds its place in the cancer immunotherapy landscape by Acharya, Nandini, Sabatos-Peyton, Catherine, Anderson, Ana Carrizosa

“…The blockade of immune checkpoint receptors has made great strides in the treatment of major cancers, including melanoma, Hodgkin’s lymphoma, renal, and lung…”
Get full text

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors by Maleki Vareki, Saman

“…Tumors responding to immune checkpoint inhibitors (ICIs) have a higher level of immune infiltrates and/or an Interferon (IFN) signature indicative of a…”
Get full text

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study by Oaknin, Ana, Gilbert, Lucy, Tinker, Anna V, Brown, Jubilee, Mathews, Cara, Press, Joshua, Sabatier, Renaud, O’Malley, David M, Samouelian, Vanessa, Boni, Valentina, Duska, Linda, Ghamande, Sharad, Ghatage, Prafull, Kristeleit, Rebecca, Leath III, Charles, Guo, Wei, Im, Ellie, Zildjian, Sybil, Han, Xinwei, Duan, Tao, Veneris, Jennifer, Pothuri, Bhavana

“…BackgroundDostarlimab is a humanized monoclonal antibody that binds with high affinity to PD-1, resulting in inhibition of binding to PD-L1 and PD-L2. We…”
Get full text

Clinical landscape of oncolytic virus research in 2020 by Macedo, Nicholas, Miller, David M, Haq, Rizwan, Kaufman, Howard L

“…Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the current landscape of OV clinical trials…”
Get full text